Bioleaders Corporation (142760) - Net Assets
Based on the latest financial reports, Bioleaders Corporation (142760) has net assets worth ₩33.09 Billion KRW (≈ $22.43 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩52.43 Billion ≈ $35.53 Million USD) and total liabilities (₩19.34 Billion ≈ $13.11 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Bioleaders Corporation's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩33.09 Billion |
| % of Total Assets | 63.12% |
| Annual Growth Rate | 23.57% |
| 5-Year Change | 21.9% |
| 10-Year Change | N/A |
| Growth Volatility | 75.7 |
Bioleaders Corporation - Net Assets Trend (2015–2024)
This chart illustrates how Bioleaders Corporation's net assets have evolved over time, based on quarterly financial data. Also explore Bioleaders Corporation assets under control for the complete picture of this company's asset base.
Annual Net Assets for Bioleaders Corporation (2015–2024)
The table below shows the annual net assets of Bioleaders Corporation from 2015 to 2024. For live valuation and market cap data, see how much is Bioleaders Corporation worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩37.31 Billion ≈ $25.28 Million |
+4.22% |
| 2023-12-31 | ₩35.79 Billion ≈ $24.26 Million |
+65.05% |
| 2022-12-31 | ₩21.69 Billion ≈ $14.70 Million |
-51.93% |
| 2021-12-31 | ₩45.11 Billion ≈ $30.57 Million |
+47.41% |
| 2020-12-31 | ₩30.60 Billion ≈ $20.74 Million |
+28.49% |
| 2019-12-31 | ₩23.82 Billion ≈ $16.14 Million |
+1.36% |
| 2018-12-31 | ₩23.50 Billion ≈ $15.92 Million |
-33.18% |
| 2017-12-31 | ₩35.17 Billion ≈ $23.83 Million |
+101.38% |
| 2016-12-31 | ₩17.46 Billion ≈ $11.83 Million |
+214.49% |
| 2015-12-31 | ₩5.55 Billion ≈ $3.76 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bioleaders Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12096050155000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩18.87 Billion | 50.58% |
| Other Components | ₩176.18 Billion | 472.26% |
| Total Equity | ₩37.31 Billion | 100.00% |
Bioleaders Corporation Competitors by Market Cap
The table below lists competitors of Bioleaders Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Everest Metals Corporation Ltd
AU:EMC
|
$20.99 Million |
|
Bluglass Ltd
AU:BLG
|
$20.99 Million |
|
Celulosa Argentina SA
BA:CELU
|
$21.00 Million |
|
UTSTARCOM HLDGS DL-0015
F:UT5
|
$21.01 Million |
|
Wealth Minerals Ltd.
V:WML
|
$20.97 Million |
|
Minesto AB
ST:MINEST
|
$20.97 Million |
|
Japan Gold Corp
V:JG
|
$20.95 Million |
|
SHINWON CONSTRUCTION COMPANY Ltd
KQ:017000
|
$20.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioleaders Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 32,989,045,530 to 37,305,571,860, a change of 4,316,526,330 (13.1%).
- Net loss of 6,993,909,580 reduced equity.
- Share repurchases of 10,999,999,750 reduced equity.
- New share issuances of 10,999,999,750 increased equity.
- Other factors increased equity by 11,310,435,910.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-6.99 Billion | -18.75% |
| Share Repurchases | ₩11.00 Billion | -29.49% |
| Share Issuances | ₩11.00 Billion | +29.49% |
| Other Changes | ₩11.31 Billion | +30.32% |
| Total Change | ₩- | 13.08% |
Book Value vs Market Value Analysis
This analysis compares Bioleaders Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.64x to 0.80x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1234.18 | ₩793.00 | x |
| 2017-12-31 | ₩1930.51 | ₩793.00 | x |
| 2018-12-31 | ₩1285.57 | ₩793.00 | x |
| 2019-12-31 | ₩1176.11 | ₩793.00 | x |
| 2020-12-31 | ₩1116.42 | ₩793.00 | x |
| 2021-12-31 | ₩1574.19 | ₩793.00 | x |
| 2022-12-31 | ₩689.60 | ₩793.00 | x |
| 2023-12-31 | ₩1022.12 | ₩793.00 | x |
| 2024-12-31 | ₩988.62 | ₩793.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioleaders Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -44.75%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.67x
- Recent ROE (-18.75%) is above the historical average (-79.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -335.69% | -1260.95% | 0.15x | 1.72x | ₩-19.19 Billion |
| 2016 | -33.76% | -235.76% | 0.12x | 1.24x | ₩-7.64 Billion |
| 2017 | -18.90% | -87.38% | 0.20x | 1.07x | ₩-10.16 Billion |
| 2018 | -73.32% | -20.02% | 0.56x | 6.52x | ₩-19.58 Billion |
| 2019 | -117.75% | -38.48% | 0.49x | 6.22x | ₩-30.43 Billion |
| 2020 | -69.07% | -26.27% | 0.42x | 6.23x | ₩-24.20 Billion |
| 2021 | -43.82% | -19.54% | 0.54x | 4.19x | ₩-24.28 Billion |
| 2022 | -106.69% | -23.04% | 0.68x | 6.84x | ₩-25.31 Billion |
| 2023 | 24.28% | 43.90% | 0.37x | 1.49x | ₩4.71 Billion |
| 2024 | -18.75% | -44.75% | 0.25x | 1.67x | ₩-10.72 Billion |
Industry Comparison
This section compares Bioleaders Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $403,359,376,260
- Average return on equity (ROE) among peers: 3.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioleaders Corporation (142760) | ₩33.09 Billion | -335.69% | 0.58x | $20.99 Million |
| ORIENTBIO Inc. (002630) | $62.65 Billion | -31.14% | 0.34x | $42.67 Million |
| Green Cross (005250) | $1.91 Trillion | 2.89% | 0.83x | $424.80 Million |
| Green Cross Holdings Preference Shares (005257) | $1.67 Trillion | 10.22% | 0.94x | $3.72 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $823.44 Million |
| GeneOne Life Science Inc (011000) | $33.79 Billion | 0.00% | 0.20x | $48.33 Million |
| HLB Co. Ltd (028300) | $21.19 Billion | 0.00% | 1.56x | $5.41 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $18.95 Million |
| Seoulin Bioscience Co.Ltd (038070) | $59.71 Billion | 14.88% | 0.35x | $37.75 Million |
| Hyundai Bioscience Co. Ltd (048410) | $64.08 Billion | 0.00% | 2.13x | $937.21 Million |
| iNtRON Biotechnology Inc (048530) | $106.18 Billion | 5.38% | 0.33x | $74.45 Million |
About Bioleaders Corporation
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and… Read more